Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis

Kim, Jung Han; Kim, Hyeong Su; Kim, Bum Jun; Han, Boram; Choi, Dae Ro; Kwon, Jung Hye

doi:10.7150/jca.26830



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(22):4279-4286. doi:10.7150/jca.26830 This issue Cite

Research Paper

Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis

Jung Han Kim^1*✉, Hyeong Su Kim^1*, Bum Jun Kim^1,2, Boram Han¹, Dae Ro Choi¹, Jung Hye Kwon¹

1. Division of Hemato-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea
2. Department of Internal Medicine, National Army Capital Hospital, The Armed Forces Medical Command, Sungnam, Gyeonggi-Do, Republic of Korea
* JH Kim and HS Kim equally contributed to this work.

Citation:

Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH. Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J Cancer 2018; 9(22):4279-4286. doi:10.7150/jca.26830. https://www.jcancer.org/v09p4279.htm

Other styles

Abstract

Thyroid transcription factor-1 (TTF-1) is overexpressed in up to 95% of primary lung adenocarcinoma while negative for almost all squamous cell carcinomas. TTF-1 expression has been investigated as a prognostic factor in non-small-cell lung cancer (NSCLC) with conflicting results. We conducted this meta-analysis to gain a better insight into the prognostic role of TTF-1 in patients only with non-squamous (non-SQ) NSCLC. A systematic computerized search of the electronic databases including PubMed, PMC, EMBASE, Web of Science, and Cochrane Library was performed. From 21 studies, 6,451 patients were included in the combined analysis of hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival. Compared with patients with non-SQ NSCLC showing negative TTF-1 expression, those with tumors harboring TTF-1 overexpression had significantly better survival (HR = 0.49, 95% CI: 0.42-0.57, p < 0.00001). Subgroup analyses revealed that TTF-1 expression significantly correlated with a better prognosis in stage I (HR = 0.65, 95% CI: 0.50-0.84, p = 0.0008) as well as stage III-IV non-SQ NSCLC (HR = 0.38, 95% CI: 0.29-0.49, p < 0.00001). In conclusion, this meta-analysis demonstrates that TTF-1 overexpression is a favorable prognostic factor in patients with non-SQ NSCLC. The subgroup analyses indicate that TTF-1 is a good prognostic marker for survival not only in early-stage but also in advanced non-SQ NSCLC.

Keywords: TTF-1, prognosis, non-small-cell lung cancer, meta-analysis

Citation styles

APA

Kim, J.H., Kim, H.S., Kim, B.J., Han, B., Choi, D.R., Kwon, J.H. (2018). Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. Journal of Cancer, 9(22), 4279-4286. https://doi.org/10.7150/jca.26830.

ACS

Kim, J.H.; Kim, H.S.; Kim, B.J.; Han, B.; Choi, D.R.; Kwon, J.H. Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J. Cancer 2018, 9 (22), 4279-4286. DOI: 10.7150/jca.26830.

NLM

CSE

Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH. 2018. Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J Cancer. 9(22):4279-4286.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.